Back
Anemia is one of the most common complications among patients with chronic kidney disease (CKD), significantly impacting their quality of life. As the CKD worsens prevalence of anemia increases in patients. The current standard of care in Anemia of CKD is IV/ Oral Iron and Erythropoietin analogues. Novel treatment Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) - Desidustat endogenously stimulates the Erythropoietin production. Hence, this retrospective analysis is planned to look in to real world outcome of Desidustat in CKD – Anemia.
This is a retrospective observational study in which we analyzed a cohort of 72 patients. They were administered Desidustat 100mg, along with oral iron (ferrous ascorbate), at our center for a period exceeding one year, with an average follow-up of patients around 60 days at our clinic.
In current study 72 patients, 14 (%) on dialysis, 57 (%) pre-dialysis, and 1 (%) post-transplant. The baseline mean hemoglobin was 9.48 ± 1.76 gm/dL. An increase in hemoglobin was observed from baseline (day 0) to day 82 ± 53.87 (follow-up). 1), reaching 10.09 ± 2.67 gm/dL. The rise in Hb was sustained at the second follow-up, conducted 158 ± 53.13 days later. At the fourth follow-up, hemoglobin levels reached 10.97 ± 1.43, and this increase was statistically significant (p < 0.05). In the most recent follow-up, the mean hemoglobin level in the overall population was found to be statistically significant (p< 0.05), measuring 11.38 ± 1.62 gm/dL. With Desidustat treatment, (n=18, 12.66%) of patients showed an increase of more than 2 mg/dL in their hemoglobin levels, demonstrating a significant effect in the treatment of anemia associated with chronic kidney disease (CKD). In current study of CKD - Anemia patients were ESA-naïve and received oral Ferrous ascorbate for iron supplementation. In our study, patient maintained good compliance with Desidustat treatment. Adverse drug reactions observed like constipation (n=3, 4.1%), edema(n=2,2.7%), abdominal pain (n=1,1.38%) and vomiting (n=1,1.38%). Current study is a retrospective in nature need of prospective study with regular follow up is recommended.
Desidustat represents a significant improvement in Hb in patients with CKD-anemia. Desidustat oral administration helps with good compliance. A prospective study It is recommended to look for efficacy and safety of Desidustat in CKD-anemia patients.